JPS6353984B2 - - Google Patents
Info
- Publication number
- JPS6353984B2 JPS6353984B2 JP16290980A JP16290980A JPS6353984B2 JP S6353984 B2 JPS6353984 B2 JP S6353984B2 JP 16290980 A JP16290980 A JP 16290980A JP 16290980 A JP16290980 A JP 16290980A JP S6353984 B2 JPS6353984 B2 JP S6353984B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- group
- general formula
- reaction
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000005379 cyclohexanecarboxylic acid derivatives Chemical class 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000000862 absorption spectrum Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- -1 etc.) Chemical group 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960000401 tranexamic acid Drugs 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000003171 anti-complementary effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OHIRZNAJMCASJT-AULYBMBSSA-N C1C[C@@H](C(=O)O)CC[C@@H]1CN=CC1=CC=C(Cl)C=C1 Chemical compound C1C[C@@H](C(=O)O)CC[C@@H]1CN=CC1=CC=C(Cl)C=C1 OHIRZNAJMCASJT-AULYBMBSSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- QVYYEGRMCQYDSE-HDJSIYSDSA-N OC(=O)[C@H]1CC[C@H](CN=Cc2ccccc2)CC1 Chemical compound OC(=O)[C@H]1CC[C@H](CN=Cc2ccccc2)CC1 QVYYEGRMCQYDSE-HDJSIYSDSA-N 0.000 description 1
- XSZOIIALDRPZQP-HDJSIYSDSA-N OC([C@H]1CC[C@H](CNCC2=CC=CC=C2)CC1)=O Chemical compound OC([C@H]1CC[C@H](CNCC2=CC=CC=C2)CC1)=O XSZOIIALDRPZQP-HDJSIYSDSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- AAZYNPCMLRQUHI-UHFFFAOYSA-N propan-2-one;2-propan-2-yloxypropane Chemical compound CC(C)=O.CC(C)OC(C)C AAZYNPCMLRQUHI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Description
本発明は一般式() 〔式中、Aは The present invention is based on the general formula () [In the formula, A is
【式】(但し、式中Yは水
素原子、ハロゲン原子、低級アルコキシ基、ニト
ロ基、アミノ基又はトリフルオロメチル基を意味
する)又はピリジル基を意味する〕で表わされる
新規なシクロヘキサンカルボン酸誘導体に関する
ものである。
前記一般式()におけるAについて更に具体
的に説明すると、AのA novel cyclohexanecarboxylic acid derivative represented by the formula It is related to. To explain A in the general formula () more specifically, A's
【式】におけるY
なる置換基は水素原子、ハロゲン原子(例えば塩
素、臭素、沃素、弗素等)、低級アルコキシ基
(例えばメトキシ基、エトキシ基、プロポキシ基、
ブトキシ基等)、ニトロ基、アミノ基等が任意の
位置に1〜3個置換されることを意味し、又、ピ
リジル基は2−ピリジル基、3−ピリジル基、4
−ピリジル基を意味する。
近年、抗プラスミン作用を有するトランス−4
−アミノメチルシクロヘキサンカルボン酸(トラ
ネキサム酸)及びその誘導体に関する研究が活発
に行なわれ、抗潰瘍作用、抗腫瘍作用等の薬理作
用が見出された。又、トラネキサム酸は作用は弱
いが抗補体作用を有することが報告されている。
そこで本発明者等はトラネキサム酸の抗補体作
用に興味を持ち、更に優れた作用を有する薬剤の
開発を目的として、一連の新規なトラネキサム酸
誘導体の合成を行ないその薬理作用の検索を行な
つた。その結果、本発明の化合物は顕著な抗補体
作用を有し、腎炎、リウマチ、膠原病、自己免疫
疾患等のアレルギー性疾患の予防及び治療剤とし
て有用であることが判明した。又抗プラスミン、
抗腫瘍、抗潰瘍、抗血栓、抗コレステロール作用
をも有し、医薬品として有用な化合物である。
本発明に係る一般式()で示されるシクロヘ
キサンカルボン酸誘導体は以下に示す製造法に従
つて製造される。
但し、式中Aは前記と同じ意味を有する。
但し、式中Aは前記と同じ意味を有する。
但し、式中Xは塩素原子及び臭素原子等のハロ
ゲン原子又は反応性スルホン酸残基を意味し、A
は前記と同じ意味を有する。
前記各製造法について更に具体的に説明する
と、製造法Aは一般式()で表わされるトラネ
キサム酸と一般式()で表わされる芳香族アル
デヒドを反応に関与しない有機溶媒(例えばメタ
ノール、エタノール、テトラヒドロフラン、ジグ
リム等)中、還元剤(例えばパラジウム−カーボ
ン等)を加えて室温もしくは加熱下において常圧
又は加圧下(0.1〜10Kg/cm)で反応を行うこと
により一般式()で表わされる目的化合物を得
ることができる。
製造法Bは一般式()で表わされるシツフ塩
基誘導体を還元剤(例えば水素化ホウ素ナトリウ
ム、水素化ホウ素カリウム、パラジウム−カーボ
ン等)の存在下、反応に関与しない有機溶媒(例
えば水、メタノール、エタノール、テトラヒドロ
フラン、酢酸等)中、氷冷下あるいは室温又は加
熱下において、常圧又は加圧下(0.1〜10Kg/cm2)
で反応を行うことにより一般式()で表わされ
る目的化合物を得ることができる。
製造法Cは一般式()で表わされる反応性誘
導体を反応に関与しない有機溶媒(水、テトラヒ
ドロフラン、ジオキサン、ベンゼン、トルエン、
キシレン、ピリジン、ジメチルホルムアミド、ヘ
キサメチルホスホリツクトリアミド等)中、加熱
下において反応を行なうことにより一般式()
で表わされる目的化合物を得ることができる。
製造法Dは一般式()で表わされるニトロ体
を還元剤(ラネ−ニツケル、酸化白金、パラジウ
ム−カーボン等)の存在下、反応に関与しない有
機溶媒(例えばメタノール、エタノール、酢酸
等)中、室温又は加熱下に常圧あるいは加圧下で
反応を行なうことにより一般式()で表わされ
るアミノ体を好収率で得ることができる。
かくして得られた化合物は所望により無機塩
(例えばカリウム、カルシウム、ナトリウム、ア
ルミニウム、塩酸等)又は有機塩(例えばアルギ
ニン、リジン等のアミノ酸塩及びジメチルアミノ
エタノール等)に導くことができる。
以下に実施例を示し本発明を更に具体的に説明
する。
実施例 1
メタノール50ml中にトランス−4−ベンジリデ
ンアミノメチルシクロヘキサンカルボン酸2.45g
を加え、氷冷下に水素化ホウ素ナトリウム0.76g
を徐々に加えた。次いで室温の状態で8時間反応
させ、溶媒を減圧下にて留去し残渣に水を加え希
酢酸にて弱酸性とし、析出する結晶を取、乾燥
後、エタノール−水(8:2)にて再結晶すると
無色プリズム晶のトランス−4−ベンジルアミノ
メチルシクロヘキサンカルボン酸2.2gを得た。
この物質の融点、赤外吸収スペクトル、マスス
ペクトル及び元素分析値は次の通りであつた。
融点 233〜235℃
赤外吸収スペクトル νc=o 1640cm-1
マススペクトル M+ 247
元素分析値 C15H21NO2
理論値 C:72.84 H:8.56 N:5.66
実測値 C:72.96 H:8.43 N:5.82
実施例 2
エタノール150ml中にトランス−4−(p−クロ
ルベンジリデン)アミノメチルシクロヘキサンカ
ルボン酸2.8g及び10%のパラジウム−カーボン
1.0gを加え接触還元を0.5Kg/cm2にて行なつた。
理論量の水素を吸収した時点で反応をやめ、反応
溶液を過し、液を減圧下に濃縮すると結晶が
析出するのでこれを取、乾燥後更にアセトンに
て再結晶すると無色プリズム晶のトランス−4−
(p−クロルベンジル)アミノメチルシクロヘキ
サンカルボン酸2.6gを得た。
この物質の融点、赤外吸収スペクトル、マスス
ペクトル及び元素分析値は次の通りであつた。
融点 225〜226℃
赤外吸収スペクトル νc=o 1640cm-1
マススペクトル M+ 281
元素分析値 C15H20ClNO2
理論値 C:63.71 H:7.13 N:4.95
実測値 C:63.82 H:7.05 N:4.88
実施例 3
トランス−4−アミノメチルシクロヘキサンカ
ルボン酸3.14gと−イソニコチンアルデヒド2.14
g及び10%パラジウム−カーボン2.5gをエタノ
ール100ml中に加え80〜100℃に加熱下接触還元を
4時間行なつた。反応溶液を過し液を減圧濃
縮し、析出する結晶を取、更にメタノールより
再結晶すると無色プリズム晶のトランス−4−
(4′−ピリジルメチル)アミノメチルシクロヘキ
サンカルボン酸2.5gを得た。
この物質の融点、赤外吸収スペクトル、マスス
ペクトル及び元素分析値は次の通りであつた。
融点 186〜188℃
赤外吸収スペクトル νc=o
マススペクトル M+ 248
元素分析値 C14H20N2O2
理論値 C:67.71 H:8.12 N:11.28
実測値 C:67.61 H:8.04 N:11.36
実施例 4
トランス−4−(p−ニトロベンジル)アミノ
メチルシクロヘキサンカルボン酸2.9gと酸化白
金0.3gをメタノール酢酸(9.5:0.5)50ml中に加
え、室温下、1〜2Kg/cm2にて接触還元を行なつ
た。理論量の水素を吸収した時点で反応をやめ、
反応溶液を過し、液を減圧濃縮し、析出する
結晶を取、更にアセトン−イソプロピルエーテ
ルの混合溶媒より再結晶すると淡黄色プリズム晶
のトランス−4−(p−アミノベンジル)アミノ
メチルシクロヘキサンカルボン酸2.4gを得た。
この物質の融点、赤外吸収スペクトル、マスス
ペクトル及び元素分析値は次の通りであつた。
融点 208〜210℃
赤外吸収スペクトル νc=o
マススペクトル M+ 262
元素分析値 C15H22N2O2
理論値 C:68.67 H:8.45 N:10.68
実測値 C:68.76 H:8.31 N:10.78
実施例 5〜12
実施例1〜4の方法に準じて次表の本発明化合
物を合成した。The substituent Y in [Formula] is a hydrogen atom, a halogen atom (e.g., chlorine, bromine, iodine, fluorine, etc.), a lower alkoxy group (e.g., a methoxy group, an ethoxy group, a propoxy group,
butoxy group, etc.), nitro group, amino group, etc. at any position, and pyridyl group means 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, etc.
-Means a pyridyl group. In recent years, trans-4, which has an anti-plasmin effect, has been
-Aminomethylcyclohexanecarboxylic acid (tranexamic acid) and its derivatives have been actively researched, and pharmacological effects such as antiulcer and antitumor effects have been discovered. Furthermore, tranexamic acid has been reported to have anti-complementary action, although the action is weak. Therefore, the present inventors became interested in the anti-complementary action of tranexamic acid, and with the aim of developing a drug with even better action, we synthesized a series of new tranexamic acid derivatives and investigated their pharmacological actions. Ta. As a result, it was found that the compound of the present invention has a remarkable anti-complement effect and is useful as a prophylactic and therapeutic agent for allergic diseases such as nephritis, rheumatism, collagen disease, and autoimmune diseases. Also anti-plasmin,
It also has antitumor, antiulcer, antithrombotic, and anticholesterol effects, making it a useful compound as a pharmaceutical. The cyclohexanecarboxylic acid derivative represented by the general formula () according to the present invention is produced according to the production method shown below. However, A in the formula has the same meaning as above. However, A in the formula has the same meaning as above. However, in the formula, X means a halogen atom such as a chlorine atom and a bromine atom, or a reactive sulfonic acid residue, and A
has the same meaning as above. To explain each of the above-mentioned production methods in more detail, production method A uses tranexamic acid represented by the general formula () and an aromatic aldehyde represented by the general formula () in an organic solvent that does not participate in the reaction (for example, methanol, ethanol, tetrahydrofuran). , diglyme, etc.), add a reducing agent (e.g., palladium-carbon, etc.) and conduct the reaction at room temperature or under heating at normal pressure or under pressure (0.1 to 10 Kg/cm) to obtain the target compound represented by the general formula (). can be obtained. In production method B, a Schiff base derivative represented by the general formula () is treated in the presence of a reducing agent (e.g., sodium borohydride, potassium borohydride, palladium-carbon, etc.) in an organic solvent that does not participate in the reaction (e.g., water, methanol, ethanol, tetrahydrofuran, acetic acid, etc.) under ice-cooling, room temperature, or heating under normal pressure or increased pressure (0.1 to 10 Kg/cm 2 )
By carrying out the reaction, the target compound represented by the general formula () can be obtained. Production method C uses a reactive derivative represented by the general formula () in an organic solvent that does not participate in the reaction (water, tetrahydrofuran, dioxane, benzene, toluene,
By carrying out the reaction under heating in xylene, pyridine, dimethylformamide, hexamethylphosphoric triamide, etc.), the general formula ()
The target compound represented by can be obtained. Production method D involves the production of a nitro compound represented by the general formula () in the presence of a reducing agent (Raney-nickel, platinum oxide, palladium-carbon, etc.) in an organic solvent that does not participate in the reaction (for example, methanol, ethanol, acetic acid, etc.). The amino compound represented by the general formula () can be obtained in good yield by carrying out the reaction at room temperature or under heating and normal pressure or increased pressure. The compound thus obtained can be converted into an inorganic salt (eg, potassium, calcium, sodium, aluminum, hydrochloric acid, etc.) or an organic salt (eg, amino acid salts such as arginine, lysine, dimethylaminoethanol, etc.) as desired. EXAMPLES The present invention will be explained in more detail with reference to Examples below. Example 1 2.45 g of trans-4-benzylideneaminomethylcyclohexanecarboxylic acid in 50 ml of methanol
and 0.76g of sodium borohydride under ice cooling.
was added gradually. Next, the reaction was allowed to proceed at room temperature for 8 hours, the solvent was distilled off under reduced pressure, water was added to the residue, and the residue was made weakly acidic with dilute acetic acid. The precipitated crystals were collected, dried, and then dissolved in ethanol-water (8:2). Recrystallization was performed to obtain 2.2 g of colorless prismatic crystals of trans-4-benzylaminomethylcyclohexanecarboxylic acid. The melting point, infrared absorption spectrum, mass spectrum, and elemental analysis values of this substance were as follows. Melting point 233-235℃ Infrared absorption spectrum νc=o 1640cm -1 Mass spectrum M + 247 Elemental analysis value C 15 H 21 NO 2 Theoretical value C: 72.84 H: 8.56 N: 5.66 Actual value C: 72.96 H: 8.43 N: 5.82 Example 2 2.8 g of trans-4-(p-chlorobenzylidene)aminomethylcyclohexanecarboxylic acid and 10% palladium-carbon in 150 ml of ethanol.
1.0 g was added to carry out catalytic reduction at 0.5 Kg/cm 2 .
When the theoretical amount of hydrogen has been absorbed, the reaction is stopped, the reaction solution is filtered, and the liquid is concentrated under reduced pressure to precipitate crystals, which are removed, dried, and then recrystallized with acetone to form colorless prism crystals. 4-
2.6 g of (p-chlorobenzyl)aminomethylcyclohexanecarboxylic acid was obtained. The melting point, infrared absorption spectrum, mass spectrum, and elemental analysis values of this substance were as follows. Melting point 225-226℃ Infrared absorption spectrum νc=o 1640cm -1 Mass spectrum M + 281 Elemental analysis value C 15 H 20 ClNO 2 Theoretical value C: 63.71 H: 7.13 N: 4.95 Actual value C: 63.82 H: 7.05 N: 4.88 Example 3 3.14 g of trans-4-aminomethylcyclohexanecarboxylic acid and 2.14 g of -isonicotinaldehyde
g and 2.5 g of 10% palladium-carbon were added to 100 ml of ethanol, and catalytic reduction was carried out under heating at 80 to 100° C. for 4 hours. The reaction solution was filtered, the liquid was concentrated under reduced pressure, the precipitated crystals were collected, and recrystallized from methanol to obtain colorless prismatic crystals of trans-4-
2.5 g of (4'-pyridylmethyl)aminomethylcyclohexanecarboxylic acid was obtained. The melting point, infrared absorption spectrum, mass spectrum, and elemental analysis values of this substance were as follows. Melting point 186-188℃ Infrared absorption spectrum νc=o Mass spectrum M + 248 Elemental analysis value C 14 H 20 N 2 O 2 Theoretical value C: 67.71 H: 8.12 N: 11.28 Actual value C: 67.61 H: 8.04 N: 11.36 Example 4 2.9 g of trans-4-(p-nitrobenzyl)aminomethylcyclohexanecarboxylic acid and 0.3 g of platinum oxide were added to 50 ml of methanol acetic acid (9.5:0.5) and contacted at room temperature at 1 to 2 Kg/ cm2. I made a return. The reaction stops when the theoretical amount of hydrogen has been absorbed,
The reaction solution was filtered, the liquid was concentrated under reduced pressure, the precipitated crystals were collected, and further recrystallized from a mixed solvent of acetone-isopropyl ether to give pale yellow prismatic crystals of trans-4-(p-aminobenzyl)aminomethylcyclohexanecarboxylic acid. 2.4g was obtained. The melting point, infrared absorption spectrum, mass spectrum, and elemental analysis values of this substance were as follows. Melting point 208-210℃ Infrared absorption spectrum νc=o Mass spectrum M + 262 Elemental analysis value C 15 H 22 N 2 O 2 Theoretical value C: 68.67 H: 8.45 N: 10.68 Actual value C: 68.76 H: 8.31 N: 10.78 Examples 5-12 The compounds of the present invention shown in the following table were synthesized according to the methods of Examples 1-4.
Claims (1)
ロ基、アミノ基又はトリフルオロメチル基を意味
する)又はピリジル基を意味する〕で表わされる
シクロヘキサンカルボン酸誘導体。[Claims] 1. General formula [Wherein, A is represented by [Formula] (wherein Y means a hydrogen atom, a halogen atom, a lower alkoxy group, a nitro group, an amino group, or a trifluoromethyl group) or a pyridyl group] Cyclohexanecarboxylic acid derivative.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16290980A JPS5785346A (en) | 1980-11-18 | 1980-11-18 | Cyclohexanecarboxylic acid derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16290980A JPS5785346A (en) | 1980-11-18 | 1980-11-18 | Cyclohexanecarboxylic acid derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5785346A JPS5785346A (en) | 1982-05-28 |
JPS6353984B2 true JPS6353984B2 (en) | 1988-10-26 |
Family
ID=15763526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP16290980A Granted JPS5785346A (en) | 1980-11-18 | 1980-11-18 | Cyclohexanecarboxylic acid derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5785346A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0522215U (en) * | 1991-09-02 | 1993-03-23 | 本田技研工業株式会社 | External pipe holding structure |
USRE48565E1 (en) | 1981-11-03 | 2021-05-18 | Personalized Media Communications LLC | Providing a subscriber specific solution in a computer network |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60163813A (en) * | 1984-02-04 | 1985-08-26 | Morishita Jintan Kk | Antiplasmin drug |
CA2606804A1 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Antimicrobial agents |
JP2009533315A (en) * | 2006-04-10 | 2009-09-17 | ランバクシー ラボラトリーズ リミテッド | Antibacterial agent |
-
1980
- 1980-11-18 JP JP16290980A patent/JPS5785346A/en active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE48565E1 (en) | 1981-11-03 | 2021-05-18 | Personalized Media Communications LLC | Providing a subscriber specific solution in a computer network |
JPH0522215U (en) * | 1991-09-02 | 1993-03-23 | 本田技研工業株式会社 | External pipe holding structure |
Also Published As
Publication number | Publication date |
---|---|
JPS5785346A (en) | 1982-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4920131A (en) | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | |
KR970005927B1 (en) | Pyridine and dyridine n-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and process for preparation thereof | |
DE3834204A1 (en) | 4H-1-BENZOPYRAN-4-ON DERIVATIVES OR THEIR SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS WITH A CONTENT OF THE SAME AS ACTIVE SUBSTANCE | |
JP2001505198A (en) | Substituted dihydrobenzofurans as PDE inhibitors | |
CA3053068A1 (en) | 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors | |
JPS6033114B2 (en) | 1,2-benzisoxazole derivative | |
JPH01301661A (en) | Novel pyridyl derivative | |
US4977162A (en) | Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments | |
JPS6353984B2 (en) | ||
JPH07505394A (en) | Bridged bisaryl carbinol derivatives, compositions and uses | |
CA1208643A (en) | 1,5-diphenyl-pyrazolin-3-one compounds, process and intermediates for preparation thereof and pharmaceutical compositions containing them | |
JPH0673012A (en) | 4-iminoquinoline, its preparation and its use | |
JPS628117B2 (en) | ||
JPS62277392A (en) | Sulfenamide derivative and production thereof | |
JPH0559117B2 (en) | ||
JPS5849369A (en) | Novel imidazole compound, manufacture and analgesic antipuretic antiinflammatory drug containing same as major component | |
CA1078395A (en) | Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation | |
JPS6368568A (en) | P-aminophenol derivative | |
JPH01203351A (en) | 1,4-dihydroxynaphthalene derivative and medicine | |
JPS6127977A (en) | 4,5-dihydro-3,3-diphenyl-4-hydrocarbyl aminomethylfuran-2(3h)-one | |
SARGENT | THE SYNTHESIS OF 1-ETHYL-, 2-ETHYL-, 3-ETHYL-AND 4-ETHYL-ACRIDINE1 | |
JPH01121274A (en) | 2-substituted cycloheptimidazole derivative, antiulcer agent and production thereof | |
JPS5993080A (en) | 1,5-naphthyridinecarboxylic acid derivative | |
JPH02270868A (en) | Anti-inflammatory 1-heteroaryl-3-acyl-2-oxyindole | |
JPS6026794B2 (en) | 2-Aminochromone-3-carboxaldehyde derivative and method for producing the same |